PC
ESPR

Polar Capital’s Esperion Therapeutics ESPR Stock Holding History

Polar Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-309,456
Closed -$7.3M – 272
2015
Q3 		$7.3M Sell
309,456
-13,932
-4% -$874K 0.15% 154
2015
Q2 		$26.4M Sell
323,388
-53,665
-14% -$5.25M 0.51% 62
2015
Q1 		$34.9M Sell
377,053
-151,545
-29% -$9.78M 0.66% 48
2014
Q4 		$21.4M Buy
+528,598
New +$16.2M 0.42% 80
2014
Q3 		– Sell
-325,639
Closed -$5.16M – 274
2014
Q2 		$5.16M Sell
325,639
-78,301
-19% -$1.13M 0.11% 189
2014
Q1 		$6.11M Sell
403,940
-234,235
-37% -$3.64M 0.14% 177
2013
Q4 		$8.77M Buy
638,175
+58,175
+10% +$847K 0.21% 164
2013
Q3 		$10.9M Buy
+580,000
New +$9.74M 0.29% 128

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Polar Capital's ESPR Position: Q4 2015 in Review

Polar Capital sold out of Esperion Therapeutics (ESPR) in Q4 2015, closing a stake of 309,456 shares — an estimated $7.3M sold.

Polar Capital first reported a position in ESPR in Q3 2013 and held it in 8 quarters. The position peaked at $34.9M in Q1 2015. 113 funds tracked by Wall St. Rank hold ESPR as of Q4 2015.

  • Polar Capital reported no remaining Esperion Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Polar Capital sold 309,456 Esperion Therapeutics shares in Q4 2015, an estimated $7.3M.
  • Polar Capital first reported a position in Esperion Therapeutics in Q3 2013 and held it in 8 quarters.
  • Polar Capital's Esperion Therapeutics position peaked at $34.9M in Q1 2015.
  • 113 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2015.

Based on Polar Capital's 13F filing for Q4 2015, filed 16 Feb 2016.